Molecular Glues Clinical Trial Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
The molecular glues pipeline and clinical trial analysis report delivers important insights on ongoing research, clinical strategies, upcoming therapeutics, and commercial analysis.
Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?
A recent academic case study, published on April 22, examined using Amgen Inc's ( NASDAQ:AMGN ) Blincyto, a bispecific CD3xCD19 T-cell engager, to treat a patient with severe systemic sclerosis. The findings have implications for Cullinan Therapeutics Inc's ( NASDAQ:CGEM ) CLN-978, a similar ...
Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday? - Cullinan Therapeutics ( NASDAQ:CGEM )
A recent academic case study, published on April 22, examined using Amgen Inc's AMGN Blincyto, a bispecific CD3xCD19 T-cell engager, to treat a patient with severe systemic sclerosis. The findings have implications for Cullinan Therapeutics Inc's CGEM CLN-978, a similar CD19xCD3 bispecific T-cell ...
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day ... - Markets Insider ...
United Airlines Reports Upbeat Results, Joins Children's Place, Interactive Brokers And Other Big Stocks Moving Higher On Wednesday - United Airlines Holdings ( NASDAQ:UAL )
U.S. stocks were lower, with the Dow Jones index falling over 50 points on Wednesday. Shares of United Airlines Holdings, Inc. UAL rose sharply during Wednesday's session after the company reported better-than-expected first-quarter financial results. Revenue of $12.539 billion topped estimates ...
Cullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity - Cullinan Oncology ( NASDAQ:CGEM )
Cullinan Therapeutics Inc CGEM, formerly Cullinan Oncology Inc, announced its plans to expand into autoimmune diseases and intends to pursue the development of CLN-978 in autoimmune diseases, with systemic lupus erythematosus ( SLE ) as a first indication.
UnitedHealth Reports Upbeat Earnings, Joins Cullinan Oncology, Ericsson And Other Big Stocks Moving Higher On Tuesday - Telefonaktiebolaget L M ( NASDAQ:ERIC ) , UnitedHealth Group ( NYSE:UNH )
U.S. stocks were mostly higher, with the Dow Jones index gaining over 100 points on Tuesday. Shares of UnitedHealth Group Incorporated UNH rose sharply during Tuesday's session following better-than-expected first-quarter earnings.
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases - Cullinan Oncology ( NASDAQ:CGEM )
CLN-978 clinical development to focus exclusively on autoimmune diseases, pursuing systemic lupus erythematosus as a first indication Clinical observations from CLN-978 B-NHL study show rapid, deep, and sustained B cell depletion and clinical activity
Harbour BioMed Reports Full Year 2023 Financial Results
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, March 28, 2024 /PRNewswire/ -- Harbour BioMed ( "HBM" or the "Company".
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Cullinan remains on track to report additional solid tumor dose escalation data for CLN-619 in the second quarter of 2024 and recently received FDA clearance for an IND to evaluate CLN-619 in relapsed/refractory multiple myeloma ...
Ocuphire ( OCUP ) to Report Q4 Earnings: What's in the Cards?
Ocuphire (OCUP) is expected to provide updates on the clinical development of its lead retinal product candidate, APX3330, to treat diabetic retinopathy, in fourth-quarter 2023 earnings release.
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
Company will initiate Phase 1 study of CLN-619 for relapsed or refractory multiple myeloma, first MICA/B antibody clinical study in hematologic malignancies ...
Puma Biotechnology ( PBYI ) to Report Q4 Earnings: What's in Store?
On Puma Biotechnology's (PBYI) fourth-quarter 2023 earnings call, investors' focus is likely to be on the sales performance of its sole marketed cancer drug, Nerlynx.
Avalo ( AVTX ) to Report Q4 Earnings: What's in the Cards?
Devoid of marketed drugs, investors will focus on Avalo Therapeutics' (AVTX) lead pipeline drug when it reports fourth-quarter earnings results.
Sarepta ( SRPT ) to Report Q4 Earnings: Will It Beat Estimates?
Investors' focus will likely be on Sarepta's (SRPT) product sales of its recently-approved DMD gene therapy when it reports fourth-quarter earnings.
Perrigo ( PRGO ) to Report Q4 Earnings: What's in the Cards?
Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the top line in the soon-to-be-reported quarter.
Moderna ( MRNA ) Gears Up for Q4 Earnings: Will It Top Estimates?
Investors' focus will likely be on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates, when it reports fourth-quarter earnings.
Why Super Micro Computer Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket - Addex Therapeutics ( NASDAQ:ADXN ) , Agrify ( NASDAQ:AGFY )
Shares of Super Micro Computer, Inc. SMCI shares rose sharply in today's pre-market trading as the company posted upbeat results for its second quarter. Super Micro Computer reported quarterly earnings of $5.59 per share, beating the analyst consensus estimate of $4.93.
XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors - XOMA ( NASDAQ:XOMA ) , XOMA ( NASDAQ:XOMAO )
EMERYVILLE, Calif., Jan. 08, 2024 ( GLOBE NEWSWIRE ) -- XOMA Corporation XOMA, the biotech royalty aggregator, announced today the Board of Directors has named Owen Hughes as Chief Executive Officer and Jack L. Wyszomierski as Chairman of the Board.
HBM gets health boost from drug licensing deals - BeiGene ( NASDAQ:BGNE ) , Bristol-Myers Squibb ( NYSE:BMY )
Nona Biosciences, a subsidiary of HBM Holdings, has struck a licensing-out deal with a Pfizer-owned biotech for an initial sum of $53 million and milestone payments of up to $1.05 billion HBM Holdings boosted its revenue by 48% in the first half of this year through licensing-out partnerships and ...
Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference - Cullinan Oncology ( NASDAQ:CGEM )
CAMBRIDGE, Mass., Dec. 18, 2023 ( GLOBE NEWSWIRE ) -- Cullinan Oncology, Inc. CGEM ( "Cullinan Oncology" ) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that Chief Executive Officer, Nadim Ahmed, will present at the 42nd Annual J.P.
Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Dec. 18, 2023 ( GLOBE NEWSWIRE ) -- Cullinan Oncology, Inc. ( Nasdaq: CGEM ) ( "Cullinan Oncology" ) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that Chief Executive Officer, Nadim Ahmed, will present at the 42nd Annual ...
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
CAMBRIDGE, Mass., Dec. 14, 2023 ( GLOBE NEWSWIRE ) -- Cullinan Oncology, Inc. ( Nasdaq: CGEM ) , a biopharmaceutical company focused on modality-agnostic, targeted oncology therapies, today announced that the first patient has been dosed with CLN-617 in a Phase 1 clinical trial.
The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, and Burkitt Lymphoma | DelveInsight
The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic ... PR ...
C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment - C4 Therapeutics ( NASDAQ:CCCC )
WATERTOWN, Mass., Nov. 20, 2023 ( GLOBE NEWSWIRE ) -- C4 Therapeutics, Inc. ( C4T ) CCCC, a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today ...
Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023
Five abstracts accepted for poster presentation at the Society for Immunotherapy of Cancer 2023 Annual Meeting ...
Small-Cell Lung Cancer Market to Accelerate Substantially During the Study Period ( 2019-2032 ) , Assesses DelveInsight | Leading Companies - Amgen, Novartis, AbbVie, BMS, Clovis Oncology, Cardiff Oncology, Roche, Daiichi Sankyo
Small-Cell Lung Cancer Market to Accelerate Substantially During the Study Period ( 2019-2032 ) , Assesses ... PR ...
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
CAMBRIDGE, Mass., Aug. 09, 2023 ( GLOBE NEWSWIRE ) -- Cullinan Oncology, Inc. ( Nasdaq: CGEM ) , a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating CLN-978 for the ...
Cullinan Oncology to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., July 31, 2023 ( GLOBE NEWSWIRE ) -- Cullinan Oncology, Inc. ( Nasdaq: CGEM ) ( "Cullinan Oncology" ) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced its participation in the following upcoming investor conferences: ...
Questex's Fierce Biotech Summit Returns to Boston in October, Gathering the Industry's Most Influential Leaders to Discuss the Future of Biotech
NEW YORK, June 12, 2023 ( GLOBE NEWSWIRE ) -- Questex's Fierce Biotech, today announces the Fierce Biotech Summit, the only event that covers the entire pharma R&D spectrum, from basic research through clinical trials, will take place October 16-18 in Boston. Register here.
Why Shares of Cullinan Oncology Jumped This Week
The company's presentation at a conference got the attention of analysts and investors.
A Look Into Healthcare Sector Value Stocks - Agile Therapeutics ( NASDAQ:AGRX ) , Kiniksa Pharmaceuticals ( NASDAQ:KNSA ) , Cullinan Oncology ( NASDAQ:CGEM ) , Ocuphire Pharma ( NASDAQ:OCUP )
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.
Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023
CAMBRIDGE, Mass., April 26, 2023 ( GLOBE NEWSWIRE ) -- Cullinan Oncology, Inc. ( Nasdaq: CGEM ) , a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that the first clinical data from its Phase 1 clinical study of CLN-619 in patients with ...
Cullinan Oncology to Participate in Stifel's 2023 Targeted Oncology Days - Cullinan Oncology ( NASDAQ:CGEM )
CAMBRIDGE, Mass., April 20, 2023 ( GLOBE NEWSWIRE ) -- Cullinan Oncology, Inc.
Overview Of Value Stocks In The Healthcare Sector - AMN Healthcare Services ( NYSE:AMN ) , Cullinan Oncology ( NASDAQ:CGEM ) , Zymeworks ( NASDAQ:ZYME ) , ProPhase Labs ( NASDAQ:PRPH ) , QuidelOrtho ( NASDAQ:QDEL )
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.
Harbour BioMed Reports Full Year 2022 Financial Results
CAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands, April 3, 2023 /PRNewswire/ -- Harbour BioMed ( "HBM" or the "Company".
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines
CAMBRIDGE, Mass., March 27, 2023 ( GLOBE NEWSWIRE ) -- Cullinan Oncology, Inc. ( Nasdaq: CGEM ) , a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced the U.S. Food and Drug Administration ( FDA ) has cleared its Investigational New Drug ( IND ) ...
Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting - Cullinan Oncology ( NASDAQ:CGEM )
CLN-619 is a MICA/B directed humanized IgG1 antibody being studied in a global Phase 1 clinical trial in patients with advanced solid tumors. Initial clinical data from the ongoing trial is on-track to be released mid-2023. CLN-617 is a cytokine therapy combining IL-2 and IL-12 in a single ...
Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting
CLN-619 is a MICA/B directed humanized IgG1 antibody being studied in a global Phase 1 clinical trial in patients with advanced solid tumors. Initial clinical data from the ongoing trial is on-track to be released mid-2023.
Celularity ( CELU ) to Report Q4 Earnings: What's in the Cards?
Devoid of marketed drugs, investors will focus on updates on Celularity's (CELU) pipeline candidates when it reports its fourth-quarter earnings.
Cullinan Oncology to Participate in Cowen's 43rd Annual Health Care Conference - Cullinan Oncology ( NASDAQ:CGEM )
CAMBRIDGE, Mass., Feb. 27, 2023 ( GLOBE NEWSWIRE ) -- Cullinan Oncology, Inc. CGEM ( "Cullinan Oncology" ) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that its President and Chief Executive Officer, Nadim Ahmed, will present at Cowen's ...
Cullinan Oncology to Participate in Cowen's 43rd Annual Health Care Conference
CAMBRIDGE, Mass., Feb. 27, 2023 ( GLOBE NEWSWIRE ) -- Cullinan Oncology, Inc. ( Nasdaq: CGEM ) ( "Cullinan Oncology" ) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that its President and Chief Executive Officer, Nadim Ahmed, will present ...
Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed
CAMBRIDGE, Mass., Feb. 13, 2023 ( GLOBE NEWSWIRE ) -- Cullinan Oncology, Inc. ( Nasdaq: CGEM ) and Harbour BioMed ( HKEX: 02142 ) today announced that Cullinan Oncology has entered into an exclusive license with Harbour BioMed for the development and commercial rights of HBM7008 ( CLN-418 ) in ...
Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed - Cullinan Oncology ( NASDAQ:CGEM )
CAMBRIDGE, Mass., Feb. 13, 2023 ( GLOBE NEWSWIRE ) -- Cullinan Oncology, Inc. CGEM and Harbour BioMed ( HKEX: 02142 ) today announced that Cullinan Oncology has entered into an exclusive license with Harbour BioMed for the development and commercial rights of HBM7008 ( CLN-418 ) in the U.S.
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
CAMBRIDGE, Mass., Feb. 01, 2023 ( GLOBE NEWSWIRE ) -- Cullinan Oncology, Inc. ( Nasdaq: CGEM ) ( "Cullinan" ) , a biopharmaceutical company focused on modality-agnostic targeted oncology for patients with cancer, today announced that the compensation committee of the Company's Board of Directors ...
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
CAMBRIDGE, Mass., Feb. 01, 2023 ( GLOBE NEWSWIRE ) -- Cullinan Oncology, Inc.
Biopharma Gains Another Shot on Goal With IND Approval
January 27, 2023 ( Investorideas.com Newswire ) The firm's CD19- and CD3-targeting monoclonal antibody is now cleared for evaluation in a Phase I clinical trial, noted an H.C. Wainwright & Co. report. Cullinan Oncology Inc. ( CGEM:NASDAQ ) bispecific monoclonal antibody, CLN-978, was approved ...
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
CAMBRIDGE, Mass., Jan. 24, 2023 ( GLOBE NEWSWIRE ) -- Cullinan Oncology, Inc. ( Nasdaq: CGEM ) , a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced the U.S. Food and Drug Administration ( FDA ) has cleared its Investigational New Drug ( IND ) ...
5 Value Stocks In The Healthcare Sector - Kiniksa Pharmaceuticals ( NASDAQ:KNSA ) , Cullinan Oncology ( NASDAQ:CGEM ) , Procaps Gr ( NASDAQ:PROC ) , ITeos Therapeutics ( NASDAQ:ITOS ) , ProPhase Labs ( NASDAQ:PRPH )
A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the ...
New Executive Leadership Team Appointed to Accelerate XOMA's Differentiated Royalty Monetization Strategy
Owen Hughes appointed Executive Chairman of the Board of Directors and Brad Sitko joins as Chief Investment Officer ...
